injections? or iv therapy

Antihistamines are commonly used for allergic reactions, but there may be situations where additional treatment with adrenaline is necessary.
Important nursing considerations include noting that subcutaneous and inhalation routes for adrenaline injections are not recommended due to lower absorption rates.
Adrenaline can be effective even in patients on beta blockers; however, beta blockers can reduce its efficiency, which is crucial during acute allergic reactions or circulatory collapse.
Beyond antihistamines, adrenaline provides bronchodilation, making it a key medication in emergency settings.
In practical settings like primary health or when IV lines are available, adrenaline can be administered through the intravenous route.

Dosage recap: Adrenaline is often available in concentrations of one in one thousand or one in ten thousand.
A 1:1000 concentration means that there is 1 mg of adrenaline in 1 mL of solution, which is equivalent to 0.1%.
Adjustments to the dosage are necessary based on the patient's age and size, especially in adolescents.
Doses can typically be repeated every 5 to 15 minutes, with a maximum of three doses depending on the patient’s response.
Additional treatments at healthcare facilities may include oxygen supplementation to assist with respiratory complications.

Early diagnosis and prompt treatment are critical to managing viral infections and mitigating transmission risks.
Nurses not only provide care but also play an important role in educating patients about their condition, treatments, and precautions.
For example, understanding how viruses like HIV interact with the immune system is vital for managing patient health and educating those at risk.

HIV primarily targets CD4 T-helper cells, leading to immunosuppression, which makes the body susceptible to infections and certain cancers.
There are two main strains of HIV, with HIV-1 being the most prevalent, and it is classified as a retrovirus due to its RNA structure that relies on reverse transcriptase for replication.
The infection process begins with HIV attaching to CD4 receptors and co-receptors like CXCR4 or CCR5, allowing it to enter the host's cells and replicate.

The progression of HIV can be categorized into stages based on the count of CD4 T-cells:
Stage 1 (CD4 levels above 500 cells/mL): Often asymptomatic or with mild flu-like symptoms.
Stage 2: CD4 levels drop but symptoms may remain latent.
Stage 3 (AIDS): Significant complications and opportunistic infections arise, requiring immediate intervention.
Testing is crucial to assess the CD4 levels throughout these stages and to monitor disease progression.

HIV can be transmitted through unprotected sexual intercourse, blood transfusions, and from mother to child (perinatal transmission).
Understanding the risks helps in patient education about preventive measures and testing.

Antiretroviral therapy (ART) is fundamental for managing HIV, focusing on controlling viral replication and reducing the risk of progression to AIDS.
ART requires at least three different antiretroviral agents due to the diverse mechanisms of the virus.
Post-Exposure Prophylaxis (PEP) can significantly reduce the risk of HIV infection if administered within 72 hours following potential exposure.

Biologic therapies such as TNF inhibitors target specific pathways in immune function regulation, particularly in autoimmune diseases like rheumatoid arthritis.
Medications like infliximab are commonly used and monitored closely, especially regarding their efficacy and side effects.
In New Zealand, these treatments are provided under special authority, ensuring careful assessment before the initiation of therapy to confirm their necessity.

Regular monitoring of patients on biologics is vital, focusing on signs of infection, liver function, and blood counts.
Each treatment's efficacy can vary based on patient compliance and disease stage, highlighting the need for continual patient education and engagement in their care plans.